The Division research interest includes influenza, SARS-CoV-2 and other respiratory virus antiviral treatment and vaccinology. Prof Hung has pioneered the use of the triple combination of interferon beta-1b, lopinavir/ ritonavir and ribavirin in the treatment of hospitalized COVID-19 patients, resulting in significantly faster clinical alleviation and viral load suppression. He and his team also pioneered the application of topical imiquimod before intradermal influenza vaccination, which results in protection against heterologous non-vaccine and antigenically drifted viruses. He was also the first to prove convalescent plasma and H-IVIG reduced mortality in patients with severe influenza infection in prospective clinical trials.

Research results were published in top journals including the Lancet, the Lancet Infectious Diseases, Clinical Infectious Diseases, Emerging Infectious Diseases, eBioMedicine, eClinicalMedicine, Chest, Thorax and Vaccine.